Stock Analysis on Net
Stock Analysis on Net

Pfizer Inc. (NYSE:PFE)

Common-Size Income Statement
Quarterly Data

Beginner level

Pfizer Inc., common-size consolidated income statement (quarterly data)

Microsoft Excel LibreOffice Calc
3 months ended: Sep 27, 2020 Jun 28, 2020 Mar 29, 2020 Dec 31, 2019 Sep 29, 2019 Jun 30, 2019 Mar 31, 2019 Dec 31, 2018 Sep 30, 2018 Jul 1, 2018 Apr 1, 2018 Dec 31, 2017 Oct 1, 2017 Jul 2, 2017 Apr 2, 2017 Dec 31, 2016 Oct 2, 2016 Jul 3, 2016 Apr 3, 2016 Dec 31, 2015 Sep 27, 2015 Jun 28, 2015 Mar 29, 2015
Revenues 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00 100.00
Cost of sales -20.85 -19.33 -19.77 -20.55 -20.52 -19.42 -18.55 -22.00 -20.26 -21.65 -19.86 -23.79 -21.62 -20.65 -19.33 -23.62 -23.65 -24.14 -21.92 -24.28 -18.36 -18.39 -16.92
Gross profit 79.15% 80.67% 80.23% 79.45% 79.48% 80.58% 81.45% 78.00% 79.74% 78.35% 80.14% 76.21% 78.38% 79.35% 80.67% 76.38% 76.35% 75.86% 78.08% 75.72% 81.64% 81.61% 83.08%
Selling, informational and administrative expenses -24.86 -25.68 -23.89 -33.42 -25.71 -26.47 -25.45 -28.67 -26.27 -26.30 -26.44 -33.21 -26.58 -26.56 -25.89 -32.45 -27.28 -26.40 -26.03 -35.94 -27.05 -28.57 -28.57
Research and development expenses -19.45 -18.07 -14.33 -22.24 -18.00 -13.89 -12.98 -17.59 -15.10 -13.34 -13.51 -16.86 -14.12 -13.80 -13.37 -18.43 -14.42 -13.30 -13.31 -16.72 -14.25 -14.63 -17.35
Amortization of intangible assets -7.40 -7.67 -7.36 -8.13 -9.56 -8.93 -9.02 -8.96 -9.42 -8.84 -9.27 -8.66 -8.94 -9.37 -9.28 -8.23 -7.42 -7.31 -7.74 -6.97 -7.75 -7.36 -8.65
Restructuring charges and certain acquisition-related costs -0.03 -3.07 -0.57 -3.55 -2.88 0.87 -0.35 -6.24 -0.64 -0.33 -0.33 -0.81 -1.13 -0.54 -1.23 -5.40 -4.07 -2.40 -1.08 -3.03 -4.81 -0.73 -0.55
Operating income 27.40% 26.19% 34.08% 12.11% 23.33% 32.16% 33.65% 16.54% 28.31% 29.53% 30.60% 16.67% 27.61% 29.08% 30.91% 11.87% 23.16% 26.45% 29.92% 13.06% 27.78% 30.33% 27.95%
Gain on completion of Consumer Healthcare JV transaction 0.00 0.00 0.05 -0.01 63.78 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Other income (deductions), net -9.46 7.30 -1.83 -23.98 -2.51 -0.94 -0.70 -23.31 3.11 4.09 1.38 -9.71 -0.39 0.50 0.01 -6.17 -10.86 -8.12 -2.54 -15.58 -5.47 -0.46 0.41
Income from continuing operations before (provision) benefit for taxes on income 17.94% 33.50% 32.30% -11.89% 84.60% 31.22% 32.95% -6.77% 31.41% 33.62% 31.98% 6.96% 27.23% 29.58% 30.92% 5.69% 12.30% 18.33% 27.38% -2.52% 22.31% 29.87% 28.37%
(Provision) benefit for taxes on income 0.21 -4.40 -3.95 9.31 -24.03 6.90 -3.30 4.04 -0.50 -4.81 -4.31 82.71 -5.52 -5.72 -6.42 -0.09 -1.91 -2.65 -3.94 1.34 -4.69 -7.64 -6.50
Income from continuing operations 18.15% 29.10% 28.35% -2.58% 60.57% 38.12% 29.65% -2.73% 30.91% 28.81% 27.67% 89.67% 21.70% 23.86% 24.49% 5.61% 10.39% 15.68% 23.44% -1.18% 17.62% 22.23% 21.87%
Discontinued operations, net of tax 0.00 0.00 0.00 0.00 0.03 0.00 0.00 -0.01 0.08 0.00 -0.01 0.01 0.00 0.01 0.00 0.12 0.00 0.01 0.00 -0.03 0.07 0.01 0.05
Net income before allocation to noncontrolling interests 18.15% 29.10% 28.35% -2.58% 60.60% 38.12% 29.65% -2.74% 31.00% 28.81% 27.66% 89.68% 21.70% 23.87% 24.49% 5.72% 10.39% 15.69% 23.44% -1.21% 17.70% 22.24% 21.92%
Net income attributable to noncontrolling interests -0.07 -0.07 -0.07 -0.08 -0.03 -0.08 -0.04 -0.08 -0.06 -0.05 -0.07 -0.11 -0.14 -0.04 -0.07 -0.04 0.00 -0.12 -0.08 -0.02 -0.07 -0.08 -0.05
Net income attributable to Pfizer Inc. 18.09% 29.03% 28.28% -2.66% 60.57% 38.04% 29.61% -2.82% 30.94% 28.75% 27.59% 89.57% 21.57% 23.83% 24.42% 5.69% 10.39% 15.57% 23.36% -1.23% 17.62% 22.16% 21.87%
Preferred stock dividends, net of tax 0.00 0.00 0.00 0.01 0.00 -0.01 -0.01 0.01 0.00 -0.01 -0.01 0.00 -0.01 0.00 0.00 -0.01 0.00 0.00 0.00 0.00 0.00 -0.01 0.00
Net income attributable to Pfizer Inc. common shareholders 18.09% 29.03% 28.28% -2.65% 60.57% 38.04% 29.60% -2.81% 30.94% 28.75% 27.58% 89.57% 21.56% 23.83% 24.42% 5.68% 10.39% 15.57% 23.36% -1.23% 17.62% 22.15% 21.87%

Based on: 10-Q (filing date: 2020-11-05), 10-Q (filing date: 2020-08-06), 10-Q (filing date: 2020-05-07), 10-K (filing date: 2020-02-27), 10-Q (filing date: 2019-11-07), 10-Q (filing date: 2019-08-08), 10-Q (filing date: 2019-05-09), 10-K (filing date: 2019-02-28), 10-Q (filing date: 2018-11-08), 10-Q (filing date: 2018-08-09), 10-Q (filing date: 2018-05-10), 10-K (filing date: 2018-02-22), 10-Q (filing date: 2017-11-09), 10-Q (filing date: 2017-08-10), 10-Q (filing date: 2017-05-11), 10-K (filing date: 2017-02-23), 10-Q (filing date: 2016-11-10), 10-Q (filing date: 2016-08-11), 10-Q (filing date: 2016-05-12), 10-K (filing date: 2016-02-29), 10-Q (filing date: 2015-11-05), 10-Q (filing date: 2015-08-06), 10-Q (filing date: 2015-05-07).

Income statement item Description The company
Operating income The net result for the period of deducting operating expenses from operating revenues. Pfizer Inc.’s operating income as a percentage of revenues decreased from Q1 2020 to Q2 2020 but then slightly increased from Q2 2020 to Q3 2020.
Income from continuing operations before (provision) benefit for taxes on income Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest. Pfizer Inc.’s income from continuing operations before (provision) benefit for taxes on income as a percentage of revenues increased from Q1 2020 to Q2 2020 but then decreased significantly from Q2 2020 to Q3 2020.
Net income attributable to Pfizer Inc. The portion of profit or loss for the period, net of income taxes, which is attributable to the parent. Pfizer Inc.’s net income attributable to Pfizer Inc. as a percentage of revenues increased from Q1 2020 to Q2 2020 but then decreased significantly from Q2 2020 to Q3 2020.